| Literature DB >> 26550128 |
Yunjie Cao1, Yaojun Zhou1, Qianfeng Zhuang1, Li Cui1, Xianlin Xu1, Renfang Xu1, Xiaozhou He1.
Abstract
In this study, we report an active targeting liposomal formulation directed by a novel peptide (RGD) that specifically binds to the integrins receptors overexpressed on prostatic cancer cells. The objectives of this study were to evaluate the in vitro and in vivo tumor drug targeting delivery of RGD modified liposomes on PC-3 cells and DU145 cells. The uptake efficiency of RGD-LP was 5.2 times higher than that of LP on PC-3 cells. The uptake efficiency of RGD-LP was 3.2 times higher than that of LP on DU145 cells. The anti-proliferative activity of RGD-LP-PTX against PC-3 cells and DU145 cells were much stronger compared to that of LP-PTX and free PTX, respectively. The tumor spheroids experiment revealed that RGD-LP-PTX was more efficaciously internalized into tumor spheroids than LP in both PC-3 cells and DU145 cells. Compared to LP-PTX and free PTX, RGD-LP-PTX showed the greatest tumor growth inhibitory effect in vivo. In brief, the RGD-LP may be an efficient targeting drug delivery system for prostatic cancer.Entities:
Keywords: Prostatic cancer; integrins receptors; liposome; tumor targeting
Year: 2015 PMID： 26550128 PMCID： PMC4612813
Source DB: PubMed Journal: Int J Clin Exp Med ISSN： 1940-5901